Are there any drug interactions between tranexamic acid, medroxyprogesterone acetate (Provera), and bisoprolol (Concor)?

No Clinically Significant Drug Interactions Between Tranexamic Acid, Provera, and Concor

There are no documented pharmacokinetic or pharmacodynamic drug interactions between tranexamic acid, medroxyprogesterone acetate (Provera), and bisoprolol (Concor) that would require dose adjustments or contraindicate their concurrent use. However, the combination of tranexamic acid with medroxyprogesterone acetate warrants careful consideration due to additive thrombotic risk.

Key Interaction Concern: Thrombotic Risk

Tranexamic Acid + Hormonal Contraceptives (Including Provera)

The primary concern is the increased risk of venous thromboembolism (VTE) when combining tranexamic acid with progestogen-containing medications like Provera. The FDA drug label for tranexamic acid explicitly warns that combined use with hormonal contraception may increase the risk for thromboembolic adverse reactions and recommends using effective alternative (nonhormonal) contraception during tranexamic acid therapy 1.

• Medroxyprogesterone acetate (Provera) carries inherent thrombotic risk: Injectable medroxyprogesterone acetate is associated with a 53% increased odds of meningioma and increased VTE risk 2, 3. Oral medroxyprogesterone acetate shows a nearly 2-fold increased odds of VTE (aOR 1.98,99% CI 1.41-2.80) 3

• Tranexamic acid's antifibrinolytic mechanism: By inhibiting plasminogen activation and fibrinolysis, tranexamic acid theoretically increases thrombotic risk, though meta-analyses have not shown increased thromboembolic complications in most surgical settings 4

• Additive risk: A 2021 pharmacokinetic review specifically identified that hormonal contraceptives' thrombotic risk is "further exacerbated by the simultaneous administration of drugs like Tranexamic acid" 5

Clinical Recommendation for Combined Use

If tranexamic acid and Provera must be used together:

• Assess baseline VTE risk factors: obesity, smoking, immobilization, prior VTE, thrombophilia, recent surgery
• Use the shortest duration possible for tranexamic acid therapy
• Monitor for signs/symptoms of thrombosis: leg pain/swelling, chest pain, dyspnea, neurological symptoms
• Consider alternative progestogens with lower thrombotic risk if long-term use is needed (e.g., levonorgestrel-IUD, which showed no significant VTE association 3)
• Avoid in high-risk patients: those with prior VTE, known thrombophilia, or multiple risk factors

Bisoprolol (Concor) Interactions

Bisoprolol has no documented interactions with either tranexamic acid or medroxyprogesterone acetate.

• Tranexamic acid is eliminated primarily unchanged via renal excretion (>95%) with minimal hepatic metabolism and only 3% protein binding 1
• Medroxyprogesterone acetate is metabolized via CYP3A4 6, while bisoprolol is not a significant CYP3A4 substrate, inducer, or inhibitor
• No pharmacodynamic interactions exist between beta-blockers and these medications

Practical Management Algorithm

For patients requiring all three medications:

1. Document indication for each medication and assess if alternatives exist
2. Calculate VTE risk score (consider Caprini or similar)
3. If low VTE risk (<3% annual risk):
   • Proceed with combination therapy
   • Counsel on thrombosis warning signs
   • Limit tranexamic acid to shortest effective duration
4. If moderate-high VTE risk (≥3% annual risk):
   • Consider alternative to Provera (non-hormonal options or lower-risk progestogens)
   • If tranexamic acid is for acute bleeding, use short-term only (typically ≤7 days)
   • Consider prophylactic anticoagulation if other indications exist
5. Bisoprolol may be continued without concern for drug interactions

Common Pitfalls to Avoid

• Don't assume all progestogens carry equal VTE risk: Injectable and higher-dose oral medroxyprogesterone acetate carry significantly higher risk than levonorgestrel-IUD or low-dose norethindrone 3
• Don't use prophylactic tranexamic acid routinely: Guidelines discourage routine prophylactic use in many settings (e.g., cirrhosis patients undergoing procedures 7, routine cesarean delivery 8)
• Don't overlook renal function: Tranexamic acid requires dose adjustment in renal impairment, as it is renally cleared 1
• Don't forget to counsel patients: The FDA label specifically requires informing patients about increased thrombotic risk when combining tranexamic acid with hormonal contraception 1